Store

Home | Store | World Market for Vaccines, 2022-2027

World Market for Vaccines, 2022-2027

Publication Date: September 22, 2022

LICENSE

Clear

SKU: 22-708

Tags: COVID-19, Infectious Diseases, Pharmaceuticals, Vaccines

Pages: 190

SKU: 22-708

World Market for Vaccines, 2022-2027 provides an in-depth analysis of the global adult and pediatric preventative vaccines market.

Since the advent of the pandemic, scientists around the world have stepped up research and development of preventative vaccines that will hopefully be able to combat existing and new infectious disease threats. COVID-19 vaccines are the largest element of that growth, representing roughly two-thirds of the market. Given the persistence and variability of the COVID-19 virus, those vaccines are forecasted in the report for a five year period.

While the focus and attention on COVID-19 vaccines will drive growth in the market, and is the most exceptional element in recent years, there are many vaccine growth areas and vaccine sales growth was on an upswing for most of the past decade. Vaccines covered in the report with sizing and market share include:

Hepatitis
HPV
Influenza
Pneumococcal
Tetanus and combinations
Shingles
COVID-19
Pediatric Routine(HiB, MMR, Combinations, Polio, Varicella)
Meningitis
Pneumococcal Disease
Travel and Other

Report Highlights:

Market Overview:
- Detailed examination of the market for preventive vaccines, including historical data from 2017 and forecast data from 2022 to 2027.
- Focus on the impact of COVID-19 vaccines, which constitute roughly two-thirds of the market growth.
Market Dynamics:
- Growth fueled by favorable demographics, new product introductions, and rising usage, particularly in China and India.
- Analysis of challenges such as vaccine safety concerns, availability in developing countries, and vaccine refusal.

Technological Advancements:

Emerging Vaccines:
- Focus on both commercialized and developmental vaccines for diseases that are already preventable through vaccination.
- Discussion of selected emerging vaccines and their market potential.

Market Insights:

Competitive Landscape:
- Market forecasts, company market shares, and expert market estimates for various vaccine categories.
- Analysis of market trends in human vaccines for disease prevention.

Strategic Insights:

Preventive Healthcare:
- Detailed discussion on the importance of immunizations in public health, highlighting the success in eradicating and controlling numerous deadly diseases through vaccination.
- Emphasis on the benefits of vaccination for individual and community health, including improved quality of life and reduced healthcare costs.

Table: Global Market for Pediatric Preventive Vaccines, by Type, 2022–2027 (in millions $)

Pediatric Vaccines	2022	2027	CAGR 2022-2027
Hepatitis	$XX Million	$XX Million	XX%
Pediatric Routine (Combinations, HiB, MMR, Polio, Varicella)	$XX Million	$XX Million	XX%
Meningitis	$XX Million	$XX Million	XX%
Pneumococcal	$XX Million	$XX Million	XX%
Rotavirus	$XX Million	$XX Million	XX%
Influenza	$XX Million	$XX Million	XX%
HPV	$XX Million	$XX Million	XX%
Pandemic vaccines/COVID-19	$XX Million	$XX Million	XX%
Others	$XX Million	$XX Million	XX%
Total	$XX Million	$XX Million	XX%

Source: Kalorama Information

For further details and to purchase directly, please contact us.


Chapter 1: Executive Summary
	The Global Vaccines Industry
	Scope and Methodology
	Market Estimates and Forecasts
		Figure 1-1: Global Vaccine Market (Non-COVID Vaccine Market; COVID Vaccine Market), 2022 – 2027, $M
Chapter 2: Introduction to Vaccines
	Introduction
		Table 2-1: Global Morbidity of Vaccine Preventable Diseases in 1990 vs. 2019
		Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
	A Brief History: The Development of Vaccines
	The Human Immune System
	Vaccine Mechanism of Action
	Types of Vaccines
	Attenuated (Weakened) Live Viruses
		Figure 2-2: Attenuated Virus Production
	Killed (Inactivated) Viruses
	Toxoid Vaccines
	Genetically Engineered/Modified Vaccines
	Classification of Vaccines
	Vaccine Approval Process
	FDA EUA Approval
		Table 2-2: VAERS Table of Reportable Events Following Vaccination
	World Health Organization Prequalified Vaccines
		Table 2-3: WHO Prequalified BCG Vaccines
		Table 2-4: WHO Prequalified Cholera Vaccines
		Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
		Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
		Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
		Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
		Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
		Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
		Table 2-11: WHO Prequalified Hepatitis A Vaccines
		Table 2-12: WHO Prequalified Hepatitis B Vaccines
		Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
		Table 2-14: WHO Prequalified Influenza Vaccines
		Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
		Table 2-16: WHO Prequalified Measles Vaccines
		Table 2-17: WHO Prequalified Measles and Rubella Vaccines
		Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
		Table 2-19: WHO Prequalified Meningococcal A Vaccines
		Table 2-20: WHO Prequalified Pneumococcal Vaccines
		Table 2-21: WHO Prequalified Polio Vaccines
		Table 2-22: WHO Prequalified Rabies Vaccines
		Table 2-23: WHO Prequalified Rotavirus Vaccines
		Table 2-24: WHO Prequalified Rubella Vaccines
		Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
		Table 2-26: WHO Prequalified Typhoid Vaccines
		Table 2-27: WHO Prequalified Varicella Vaccine
		Table 2-28: WHO Prequalified Yellow Fever Vaccines
		Table 2-29: WHO Prequalified Other Vaccines
	Pandemics
	HIN1 Pandemic of 2009/2010
	Coronavirus Pandemic
		Figure 2-3: COVID-19 Per Capita Doses Purchased/Ordered by Country (through September 2022)
		Figure 2-4: Leading COVID-19 Vaccines: Government and Private Commercialization/Contracts
	Ebola Epidemics
	Manufacturing Incentives
	Synthetic Vaccines
	Artificial Intelligence Development
Chapter 3: Pediatric Preventative Vaccines
	Introduction
		Table 3-1: Global Child Immunization Rates for Vaccines Recommended by the WHO, 2019
	Childhood Immunization in the United States
	Childhood Immunization Rates
	Challenges to the Vaccine Delivery System
	Recommended Childhood Immunization Schedule
		Figure 3-1: CDC Recommended Immunization Schedule: Birth to 15 Months
		Figure 3-2: CDC Recommended Immunization Schedule: 18 Months to 18 Years
	State Immunization Recommendations
		Figure 3-3: Polar Graph on State School Vaccination Exemptions Law, United States
	COVID-19 Vaccination Schedule
		Figure 3-4: Pediatric COVID-19 Vaccination Schedule for People Not Moderately or Severely Immunocompromised
		Figure 3-5: Pediatric COVID-19 Vaccination Schedule for People Moderately or Severely Immunocompromised
	United Nations Initiatives
	Pediatric Vaccine Markets
		Table 3-2: Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others) 2022–2027, in $ Millions
		Figure 3-6: Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others) 2022–2027 (%)
		Figure 3-7: Market Share of Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others) 2022 (%)
		Pediatric Vaccines in Development
		Table 3-3: Selected Pediatric Vaccines in Development, 2022
	Competitive Summary
		Table 3-4: Major Manufacturers’ Shares of the Global Pediatric Preventative Vaccine Market, 2022 (%, $ Millions)
		Figure 3-8: 2022 Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (%)
Chapter 4: Adult Preventative Vaccines
	Introduction
	Recommended Adult Immunizations
		Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
	Global Influenza Surveillance Program
	U.S. Surveillance
		Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004 – 2022 (%)
		Figure 4-2: U.S. Influenza Vaccine Effectiveness by Season 2004-2022, (%)
	WHO International Health Regulations
	Influenza
		Figure 4-3: Estimated U.S. Flu Burden, by Season 2010-2020
		Table 4-2: Estimated Number of Influenza Illnesses Averted by Vaccination, by Age Group – United States, 2019-2020 Influenza Season
		Table 4-3: Estimated Number of Influenza Medical Visits Averted by Vaccination, by Age Group – United States, 23019-2020 Influenza Season
		Table 4-4: Estimated Number and Fraction of Influenza Hospitalizations Averted by Vaccination, by Age Group – United States, 2019-2020 Influenza Season
		Table 4-5: Estimated Number of Influenza Deaths Averted by Vaccination, by Age Group – United States, 2019-2020 Influenza Season
		Table 4-6: WHO Pandemic Classification Schedule
		Adult Preventive Vaccine Markets
		Table 4-7: Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2022–2027, in $ Millions
		Figure 4-4: Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2022–2027 (%)
		Figure 4-5: Market Share of Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2022 (%)
		Influenza Vaccine Market: Generating 26% of Total Adult Non-COVID Vaccine Sales
		Figure 4-6: U.S. Seasonal Influenza Vaccination by Age Group and Season, 2010-2022
		Figure 4-7: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target – Total Population – Seasons 2010-2020
	COVID-19 Market Size Estimates and Forecast
		Table 4-8: Global COVID-19 Vaccine Market Cumulative Value 2020-2022 ($ millions)
		Figure 4-8: Global COVID-19 Vaccine Stockpiling, Government Contracted Dose Order and Private Sale Distribution by Unit Volume, Cumulative 2020-2022, % by Country
	Adult Vaccines in Development
	COVID-19 Vaccine Development
		Figure 4-9: Regional Distribution of COVID-19 Vaccine Development
		Figure 4-10: COVID-19 Vaccine Development, Distribution by Vaccine Platform
	Competitive Summary
		Table 4-9: Major Manufacturers’ Shares of the Global Adult Preventative Vaccine Market, 2022 (%, $ Millions)
		Figure 4-11: 2022 Global Adult Preventative Vaccines Market Share, by Leading Competitors (%)
Chapter 5: Total Vaccines Market
	Trends Driving the Vaccines Market
		Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2017-2027
	Market Size and Forecast
		Table 5-1: Total Global Market for Preventive Vaccines by Type, 2022–2027, in $ Millions
		Figure 5-2: Total World Market for Vaccines by Type, 2022-2027 (Pediatric, Adult) ($ Millions)
		Figure 5-3: Total World Vaccine Market, Non-COVID and COVID Vaccine, 2022-2027
	Pediatric Vaccines
	Adult Vaccines
		Figure 5-4: Global Preventive Vaccine Market by Broad Segment (Pediatric, Adult), Trend 2017 – 2027 $millions
		Vaccine Sales by Region
		Table 5-2: Total Europe Market for Preventive Vaccines by Type, 2022–2027, in $ Millions
		Table 5-3: Total U.S. Market for Preventive Vaccines by Type, 2022–2027, in $ Millions
		Table 5-4: Total ROW Market for Preventive Vaccines by Type, 2022–2027, in $ Millions
	Vaccine Market Competitors
		Table 5-5: Major Manufacturers’ Shares of the Global Vaccine Market, 2022 (%, $ Millions)
		Figure 5-5: 2022 Global Vaccines Market Share, by Leading Competitors (%)
	Global Healthcare Mergers and Acquisitions
Chapter 6: Company Profiles
	AstraZeneca
		Table 6-1: AstraZeneca Corporate Summary
		Company Summary
		Products
	Bavarian Nordic, A/S
		Table 6-2: Bavarian Nordic A/S Corporate Summary
		Company Summary
		Products
	Bharat Biotech International Ltd.
		Table 6-3: Bharat Biotech Corporate Summary
		Company Summary
		Products
	BioNTech SE
		Table 6-4: BioNTech Corporate Summary
		Company Summary
		Products
	CSL Limited/Seqirus
		Table 6-5: CSL/Seqirus Corporate Summary
		Company Summary
		Products
	Dynavax Technologies
		Table 6-6: Dynavax Technologies Corporate Summary
		Company Summary
		Products
	Emergent BioSolutions, Inc.
		Table 6-7: Emergent BioSolutions Corporate Summary
		Company Summary
		Products
	GlaxoSmithKline, Inc.
		Table 6-8: GlaxoSmithKline Corporate Summary
		Company Summary
		Products
		Table 6-9: GSK Marketed Vaccines 2021
	Inovio Pharmaceuticals, Inc.
		Table 6-10: Inovio Corporate Summary
		Company Summary
		Products
	Johnson & Johnson/Crucell/Janssen
		Table 6-11: Johnson & Johnson Corporate Summary
		Company Summary
		Products
	Medicago, Inc.
		Table 6-12: Medicago Corporate Summary
		Company Summary
		Products
	Merck & Co, Inc.
		Table 6-13: Merck Corporate Summary
		Company Summary
		Products
	Mitsubishi Tanabe Pharma Corporation
		Table 6-14: Mitsubishi Tanabe Corporate Summary
		Company Summary
		Products
	Moderna, Inc
		Table 6-15: Moderna Corporate Summary
		Company Summary
		Products
	Novavax, Inc.
		Table 6-16: Novavax Corporate Summary
		Company Summary
		Products
	Pfizer, Inc.
		Table 6-17: Pfizer Corporate Summary
		Company Summary
		Products
	Sanofi Pasteur
		Table 6-18: Sanofi Pasteur Corporate Summary
		Company Summary
		Products
	Serum Institute, Inc.
		Table 6-19: Serum Institute of India Corporate Summary
		Company Summary
		Products
	Sinovac Biotech Ltd.
		Table 6-20: Sinovac Biotech Corporate Summary
		Company Summary
		Products
	Soligenix, Inc.
		Table 6-21: Soligenix Corporate Summary
		Company Summary
		Products
	Takeda Pharmaceutical Co, Ltd.
		Table 6-22: Takeda Pharmaceutical Corporate Summary
		Company Summary
		Products
	Valneva SE
		Table 6-23: Valneva Corporate Summary
		Company Summary
		Products

Related products

Hematology and Coagulation Markets, 2023

April 5, 2023

Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.

Key Insights Provided:

Market sizing…

Price range: $3,000.00 through $4,500.00

The Worldwide Market for Clinical Laboratory Services, 9th Edition

June 25, 2024

Understanding the clinical laboratory market is crucial for effective business planning. The Worldwide Market for Clinical Laboratory Services, 9th Edition answers essential questions such as the size of the service market for clinical testing, the types of tests that are in demand, and the future trajectory of this market 2023-2028. It also identifies the companies…

Price range: $5,000.00 through $7,500.00

The World Market for Veterinary Diagnostics, 7th Edition

January 22, 2024

Unlock the potential of the veterinary diagnostics market with Kalorama Information’s comprehensive report, The World Market for Veterinary Diagnostics, 7th Edition, which dives deep into the world of animal healthcare diagnostics. From disease identification to monitoring, veterinarians rely on a variety of tests for accurate diagnoses and effective treatment plans. Our report provides a detailed…

Price range: $5,000.00 through $7,875.00

Clinical Laboratory Services Market, 8th Edition

Laboratories are the workhorse of diagnostic services for the IVD market. These laboratories play a vital role in providing analysis of a wide range of disorders and diseases including pathology, immunology, cholesterol testing, allergy testing, urinalysis, genetic testing and many more. Kalorama Information’s Clinical Laboratory Services Market, 8th Edition is your comprehensive resource for insights…

Price range: $4,000.00 through $6,000.00

Histology and Cytology IVD Market Update, 2024

Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.

Histology and Cytology IVD Market Update, 2024 provides an in-depth competitive analysis…

Price range: $5,000.00 through $7,875.00

In Vitro Diagnostics Business Outlook, 2024

In Vitro Diagnostics Business Outlook, 2024 is a must-have publication offering exclusive information and data that cannot be found elsewhere. With a focus on the in vitro diagnostics (IVD) market, this publication provides valuable insights to help businesses identify growth opportunities, understand market trends, and tailor strategies for success.

Key Features:

…

Price range: $4,995.00 through $9,995.00